Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of EGF. Reveromycin A displays antiproliferative behaviour against human cell lines KB and K562, as well as potent antifungal activity. More recently it has been shown to induce apoptosis in osteoclasts thus inhibiting bone resorption.
Reveromycin A is soluble in ethanol, methanol, DMF and DMSO.
Reveromycin A is soluble in ethanol, methanol, DMF and DMSO.
| Mechanism of Action | Reveromycin A is a G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. |
| References | Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Woo J.T. et al. Proc Natl Acad Sci USA. 2006, 103, 4729. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. Muguruma H. et al. Clin Cancer Res. 2005, 11, 8822. Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor Reveromycin A. Miyamoto Y., et al. , J. Biol. Chem., 2002, 277, 28810. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. Takahashi H., et al. , J. Antibiot., 1992, 45, 1414. |
